Abstract
Author(s): Deepu Daniel and Natasha Bray
Diabetes is one of the most common diseases encountered in both the outpatient and inpatient settings. According to data from the 2011 National Diabetes Fact Sheet, approximately 8.3% (25.8 million) of the entire American population have diabetes. Of this population, about 72.9% (18.8 million) have been clinically diagnosed while an estimated 27.1% (7.0 million) remainundiagnosed.AccordingtothestudyEconomicCostsofDiabetesintheU.S.in2012,thetotalnationalcostofdiagnosed diabetes,includingdirectmedicalcostandreducedproductivitywasnearly$245billion.Extensiveresearcheï¬ortshavegoneinto developing new pharmacologic agents to treat diabetes. The newest medications recently approved by the FDA are the SGLT2 inhibitors. This article will explain the mechanism of the action of this class of drugs along with their speciï¬c role in diabetic management.Thisarticlewillfocusoncanagliï¬ozinanddapagliï¬ozin,thetwomostwellresearchedandstudieddrugsofSGLT2 inhibitors,bothofwhichhavebeenapprovedforusebytheFoodandDrugAdministration.Someofthemajortrialsconcerning bothofthesedrugswillbepresentedinthisarticle.
<Share this article
